Can AstraZeneca's Motavizumab Leapfrog Synagis? Advisory Committee Will Weigh In
This article was originally published in The Pink Sheet Daily
Panel meeting on the respiratory syncytial virus product - which demonstrated non-inferiority, but not superiority, to Synagis - is set for June 2.
You may also be interested in...
AstraZeneca's biologics unit MedImmune is continuing to solidify its domination of the market for products to prevent serious respiratory syncytial virus disease in high-risk infants with a formal reply to FDA's "complete response" letter for its investigational product motavizumab
In a bid to patch over their respective weaknesses in the HIV marketplace, GlaxoSmithKline and Pfizer announced April 16 they are forming a jointly owned company combining their portfolios of existing and developing drugs
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.